Core Insights - The company, Giant Bio (02367), reported a mid-year performance for 2025 with revenue of approximately 3.113 billion yuan, representing a year-on-year growth of 22.5% [1] - Gross profit was about 2.542 billion yuan, showing a year-on-year increase of 21.5% [1] - Profit attributable to shareholders was around 1.182 billion yuan, reflecting a year-on-year growth of 20.2% [1] - Basic earnings per share stood at 1.14 yuan [1] Revenue Growth Drivers - The revenue growth was primarily driven by the company's efforts in deepening both online and offline channels, enhancing operational capabilities, consolidating the growth of star products, upgrading core products, and strengthening brand marketing to increase brand influence [1]
巨子生物公布中期业绩 归母净利约11.82亿元 同比增长20.2%